Pharmacology & Physiology

Researchers at the George Washington University found that inhibitory GABAergic interneurons in the hippocampus excite the developing brain at ages equivalent to the early third trimester.

A drug developed at the George Washington University (GW) School of Medicine and Health Sciences (SMHS), GIAPREZA, can increase dangerously low blood pressure in life-threatening situations, offering the potential to help hundreds of thousands of patients in the United States.

The National Institutes of Health awarded a research team at GW $7.8 million to establish a rare disease network for myasthenia gravis. 

The George Washington University has sold a portion of its royalty rights to sales of a drug originally developed at the School of Medicine and Health Sciences.

Matthew Colonnese, PhD, has been awarded more than $4 million for the study of early brain activity.

The GW School of Medicine and Health Sciences will have a presence at the 2019 AAAS Annual Meeting, Feb. 14–17 in Washington, D.C.

The George Washington University (GW) School of Medicine and Health Sciences has named David Mendelowitz, PhD, professor of pharmacology and physiology and anesthesiology and critical care, to serve as the interim chair of the Department of Pharmacology and Physiology.

Colin Young, PhD, received $2.4 million for his research on non-alcoholic fatty liver disease.

The study published in the Journal of Neuroscience suggests the thalamus controls the development of state dependency and continuity.

The GW Postdoc Association hosted Postdoc Appreciation Day on Sept. 21 as part of the National Postdoc Association Postdoc Appreciation Week from Sept. 17–21.